How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about zilucoplan

Marketing authorisation indication

2.1

Zilucoplan (Zilbrysq, UCB Pharma) is indicated 'as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive'.

Price

2.3

The list price of zilucoplan is £3,653.97 for 7 pre-filled syringes of 16.6 mg solution for injection, £5,041.78 for 7 pre-filled syringes of 23.0 mg solution for injection, and £7,114.70 for 7 pre-filled syringes of 32.4 mg solution for injection (all excluding VAT, BNF online, accessed June 2024).

2.4

The company has a commercial arrangement, which would have applied if zilucoplan had been recommended.